Fennec Pharmaceuticals (FRX) to Release Quarterly Earnings on Thursday

Fennec Pharmaceuticals (TSE:FRX) will be announcing its earnings results before the market opens on Thursday, November 7th. Analysts expect the company to announce earnings of C($0.19) per share for the quarter.

Fennec Pharmaceuticals (TSE:FRX) last released its quarterly earnings data on Tuesday, August 13th. The biopharmaceutical company reported C($0.27) EPS for the quarter, missing the consensus estimate of C$0.08 by C($0.35). Fennec Pharmaceuticals had a net margin of 5.59% and a negative return on equity of 1,005.59%. The firm had revenue of C$9.94 million for the quarter, compared to the consensus estimate of C$18.67 million.

Fennec Pharmaceuticals Price Performance

Shares of TSE:FRX opened at C$6.62 on Wednesday. The stock’s 50 day moving average is C$6.69 and its 200-day moving average is C$8.51. Fennec Pharmaceuticals has a twelve month low of C$5.76 and a twelve month high of C$15.43. The company has a quick ratio of 10.17, a current ratio of 8.02 and a debt-to-equity ratio of 1,040.68. The firm has a market capitalization of C$181.12 million, a price-to-earnings ratio of 60.80 and a beta of 0.25.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc operates as a biopharmaceutical company in the United States. The company's product candidate includes PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. It sells its products through regional pediatric oncology specialists and medical science liaisons.